Reminders for booster jab and repeat vaccination against COVID-19 Adults who have not yet had a booster jab or repeat vaccination against COVID-19 will receive a reminder letter from RIVM, starting Friday 8 July 2022.
SARS-CoV-2 infections rising less rapidly 39,283 positive COVID-19 tests were reported in the Netherlands last week*. That is an increase of 15% compared to the week before that. This means that the number of reported infections is still rising, but not as rapidly as in the previous weeks.
Operations postponed due to pandemic result in 320,000 healthy life years lost The COVID-19 pandemic caused over 305,000 operations to be postponed in 2020 and 2021 in the Netherlands.
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
Pressure drainage can be a cost-effective technology to reduce CO2 emissions in peatland areas Pressure drainage can in some cases help to reduce CO2 emissions in peatland areas. This intervention is very expensive and only cost-effective when it sufficiently reduces CO2 emissions.
Changed indicative magnetic field zones around overhead high-voltage lines RIVM has updated the 2005 grid map (Netkaart) showing the overhead high-voltage lines in the Netherlands.
INHERIT Model: a tool to jointly improve health, environmental sustainability and Health Equity RIVM is involved in the Horizon2020 project INHERIT. The first article of the INHERIT project has been published, lead-authored by RIVM.
RIVM on shortlist Best Government Organisation of the Year 2018 The National Institute for Public Health and the Environment (RIVM) has made the shortlist for the 2018 election for best government organisation of the year.
RIVM supports WHO in national capacity building for measuring foodborne disease burden RIVM’s Collaborating Centre for Risk Assessment of Pathogens in Food and Water was invited to WHO’s side event during the 41st Codex Alimentarius Commission on July 4th 2018.
Rapid developments in modern biotechnology are a challenge for risk assessment Due to developments in modern biotechnology, such as genome editing, synthetic biology and regulation of gene expression, many new applications are expected in the next ten years.